SYS-CON MEDIA Authors: Liz McMillan, Carmen Gonzalez, Elizabeth White, Pat Romanski, Gary Arora

News Feed Item

Updated St. Gallen International Breast Cancer Guidelines reconfirm Oncotype DX® as the only multi-gene test validated to predict chemotherapy benefit

GENEVA, May 11, 2015 /PRNewswire/ -- Genomic Health today announced that the 14th St. Gallen International Breast Cancer Conference Expert Panel, for the third time, recognised the Oncotype DX® breast cancer test for its ability to provide not only prognostic but also predictive information regarding the likelihood of chemotherapy benefit for patients with early-stage, endocrine sensitive, invasive breast cancer.

The Oncotype DX test was the only multi-gene test accepted with a strong majority of panelists supporting it as a predictive tool. The new guidelines have been recently published online in the Advance Access section of Annals of Oncology and will appear in a future print issue.

"Many newly diagnosed breast cancer patients face the difficult decision of whether or not to undergo chemotherapy," said Dr Angelo Di Leo, member of the St. Gallen Expert Panel and Head of the Medical Oncology Unit at the Hospital of Prato, Istituto Toscano Tumori, Italy. "A tool like the Oncotype DX test can be helpful in identifying the group of patients with endocrine sensitive breast cancer who are likely to derive benefit from adjuvant chemotherapy."

Criteria currently used for making chemotherapy treatment decisions in clinical practice may result in substantial overtreatment and unnecessary costs for the healthcare system. Research shows that less than 10% of patients with early-stage breast cancer actually benefit from chemotherapy1,2 and about one-third of treatment recommendations for early-stage breast cancer patients change after the use of the Oncotype DX test.3

More than 20 studies conducted in both developed and emerging markets have shown that testing with the Oncotype DX test represents a cost-effective use of healthcare resources. Results presented recently from a real-life observational study conducted in Ireland4 showed that use of the Oncotype DX test in early-stage breast cancer led to a 58 percent net reduction in chemotherapy use, resulting in net cost savings of nearly €800,000. 

Healthcare systems across Europe are recognising the value of the test. Most recently, the National Health Service (NHS) in England agreed to an access program for the Oncotype DX breast cancer test. The test is also covered in Switzerland through the mandatory health insurance system and is reimbursed by the public insurance system in Ireland and in half of the regions of Spain. 

"We are pleased that this expert panel recognised once again the value of the Oncotype DX test. An extensive body of clinical evidence highlights the unique ability of our test to play a critical role in breast cancer management by improving the quality of treatment decisions for patients while providing a positive impact on healthcare systems," said Calvin Chao, Senior Director of International Medical Affairs at Genomic Health.

The Oncotype DX breast cancer test is incorporated in all major international guidelines, including NICE, St. Gallen International Breast Cancer Expert Panel, ESMO, ASCO and NCCN. Since it became available in 2004, more than half a million tests have been requested by more than 19,000 physicians in over 70 countries.

About Genomic Health
Genomic Health, Inc. is a world-leading provider of genomic-based diagnostic tests that inform treatment decisions and help to ensure each patient receives appropriate treatment for early stage cancer. The company is applying its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey; from screening and surveillance, through diagnosis and treatment selection. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, http://www.genomichealth.com/. To learn more about the Oncotype DX test, visit: http://www.oncotypedx.com/

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the value, benefits and attributes of the company's tests to patients, physicians and payors. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

1 Paik S et al. J Clin Oncol 2006;24:3726-34.
2 Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Lancet. 2012:379;432-444.
3 Albanell, J. et al. ESMO 2012; poster 252PD.
4 Smyth L, Economic Impact of 21-gene Recurrence Score testing on Early Stage Breast Cancer in Ireland. St. Gallen 2015.

Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Blockchain has shifted from hype to reality across many industries including Financial Services, Supply Chain, Retail, Healthcare and Government. While traditional tech and crypto organizations are generally male dominated, women have embraced blockchain technology from its inception. This is no more evident than at companies where women occupy many of the blockchain roles and leadership positions. Join this panel to hear three women in blockchain share their experience and their POV on the futu...
Cloud Storage 2.0 has brought many innovations, including the availability of cloud storage services that are less expensive and much faster than previous generations of cloud storage. Cloud Storage 2.0 has also delivered new and faster methods for migrating your premises storage environment to the cloud and the concept of multi-cloud. This session will provide technical details on Cloud Storage 2.0 and the methods used to efficiently migrate from premises-to-cloud storage. This session will als...
Concerns about security, downtime and latency, budgets, and general unfamiliarity with cloud technologies continue to create hesitation for many organizations that truly need to be developing a cloud strategy. Hybrid cloud solutions are helping to elevate those concerns by enabling the combination or orchestration of two or more platforms, including on-premise infrastructure, private clouds and/or third-party, public cloud services. This gives organizations more comfort to begin their digital tr...
In very short order, the term "Blockchain" has lost an incredible amount of meaning. With too many jumping on the bandwagon, the market is inundated with projects and use cases that miss the real potential of the technology. We have to begin removing Blockchain from the conversation and ground ourselves in the motivating principles of the technology itself; whether it is consumer privacy, data ownership, trust or even participation in the global economy, the world is faced with serious problems ...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It's clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Th...
For enterprises to maintain business competitiveness in the digital economy, IT modernization is required. And cloud, with its on-demand, elastic and scalable principles has resoundingly been identified as the infrastructure model capable of supporting fast-changing business requirements that enterprises are challenged with, as a result of our increasingly connected world. In fact, Gartner states that by 2022, 28% of enterprise IT spending will have shifted to cloud. But enterprises still must d...
Cloud-Native thinking and Serverless Computing are now the norm in financial services, manufacturing, telco, healthcare, transportation, energy, media, entertainment, retail and other consumer industries, as well as the public sector. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that pro...
The level of trust we have with individuals, businesses, and technology affects our lives daily. This is important to remember when discussing new technologies. For example, our level of trust is a critical factor when evaluating a new technology as a potential solution for providing business value. Given the importance of trust, imagine one's reaction upon hearing that blockchain is a "trustless trust" system. On the surface, that does sound like an oxymoron. This paper discusses how "trustless...
Public clouds dominate IT conversations but the next phase of cloud evolutions are "multi" hybrid cloud environments. The winners in the cloud services industry will be those organizations that understand how to leverage these technologies as complete service solutions for specific customer verticals. In turn, both business and IT actors throughout the enterprise will need to increase their engagement with multi-cloud deployments today while planning a technology strategy that will constitute a ...
Data center, on-premise, public-cloud, private-cloud, multi-cloud, hybrid-cloud, IoT, AI, edge, SaaS, PaaS... it's an availability, security, performance and integration nightmare even for the best of the best IT experts. Organizations realize the tremendous benefits of everything the digital transformation has to offer. Cloud adoption rates are increasing significantly, and IT budgets are morphing to follow suit. But distributing applications and infrastructure around increases risk, introdu...
Moving to Azure is the path to digital transformation, but not every journey is effective. Organizations that start with a cohesive, well-planned migration strategy can avoid common mistakes and stay a step ahead of the competition. Learn from Atmosera CEO, Jon Thomsen about the opportunities and challenges found in three pivotal phases of the journey to the cloud: Evaluation and Architecting, Migration and Management, and Optimization & Innovation. In each phase, there are distinct insights tha...
Most modern computer languages embed a lot of metadata in their application. We show how this goldmine of data from a runtime environment like production or staging can be used to increase profits. Adi conceptualized the Crosscode platform after spending over 25 years working for large enterprise companies like HP, Cisco, IBM, UHG and personally experiencing the challenges that prevent companies from quickly making changes to their technology, due to the complexity of their enterprise. An accomp...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
Every organization is facing their own Digital Transformation as they attempt to stay ahead of the competition, or worse, just keep up. Each new opportunity, whether embracing machine learning, IoT, or a cloud migration, seems to bring new development, deployment, and management models. The results are more diverse and federated computing models than any time in our history.
Andrew Keys is co-founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereum.